Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Other Non Operating Income of -$795000.0 for Q2 2026, down 1792.86% year-over-year from $46962.0 in Q2 2025, and up 62.0% quarter-over-quarter from -$2.1 million in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Other Non Operating Income for 2 consecutive years, with -$795000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income fell 1792.86% year-over-year to -$795000.0; the TTM figure through Jun 2026 stood at -$5.7 million (down 13390.48% YoY), while the FY2025 annual figure was -$2.8 million, changed N/A from the prior year.
- Other Non Operating Income grew to -$795000.0 in Q2 2026 per MDGL's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at -$42000.0 in Q2 2025 and bottomed at -$2.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.96 Bn | 15.12 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -795,000.00 |
| Mar 31, 2026 | -2.09 Mn |
| Sep 30, 2025 | -2.78 Mn |
| Jun 30, 2025 | -42,000.00 |